Clinical Trials Logo

Clinical Trial Summary

In a population of cirrhotics patients who did not responde to an anti-HBV vaccination according to the recommended vaccination, the goal is to : Describe the proportion of patients with HBs antibody levels greater than 10mUI/mL at 1 month of the last injection of vaccine ; with a M0-M1-M6 vaccine regimen using 3 vaccines strategies : - After simple intramuscular vaccine (IM) ( Control group ) - After simple intradermal vaccine - after IMIQUIMOD's application followed by intradermal vaccine administration The main hypothesis of this study is : IMIQUIMOD acts as an immunity booster, so the combination of IMIQUIMOD with an intra-dermal injection of the anti-HBV vaccine allows better acquisition of post-vaccination immunization.


Clinical Trial Description

This study will be in a population of Cirrhotic patients who have already received a HBV vaccination with a conventional regimen and who have not responded (characterized by a level of antibody Hbs < 10UI/ml at the end of the vaccine regimen). In current recommendations, up to 3 additional injections of HBV vaccine should be injected to obtain an antibody level> 10 mIU / ml. In this study, the investigator will describe the proportion of patients with HBs antibody levels greater than 10mUI/mL at 1 month of the last injection of vaccine ; with a M0-M1-M6 vaccine regimen using 3 vaccines strategies : - After simple intramuscular vaccine (IM) ( Control group ) - After simple intradermal vaccine - after IMIQUIMOD's application followed by intradermal vaccine administration ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05028322
Study type Interventional
Source Central Hospital, Nancy, France
Contact
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2021
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04604860 - Use of EL-FIT App to Promote Physical Activity N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Recruiting NCT04581369 - Cirrhosis Medical Home N/A
Recruiting NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Recruiting NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT03437876 - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis N/A
Recruiting NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Recruiting NCT04121520 - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Not yet recruiting NCT04591522 - Fecal Microbiota Transplantation in Cirrhosis N/A
Withdrawn NCT03309592 - Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension Phase 4
Active, not recruiting NCT03969186 - Telehealth Intervention in Cirrhotics N/A
Enrolling by invitation NCT04178096 - Using Data-Driven Implementation Strategies to Improve the Quality of Cirrhosis Care N/A
Recruiting NCT04221347 - Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
Recruiting NCT04195724 - Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis N/A
Not yet recruiting NCT04592744 - Angiotensin 2 for AKI After OLT Phase 4
Recruiting NCT04322201 - Continuous Passive Paracentesis for Intra-abdominal Hypertension N/A
Completed NCT05047029 - Myocardial Fibrosis and Inflammation in Liver Cirrhosis